Curis, Inc. (NASDAQ:CRIS) Sees Large Growth in Short Interest

Curis, Inc. (NASDAQ:CRIS) saw a large increase in short interest in October. As of October 31st, there was short interest totalling 137,000 shares, an increase of 26.6% from the October 15th total of 108,200 shares. Based on an average daily trading volume, of 55,800 shares, the days-to-cover ratio is currently 2.5 days. Approximately 1.8% of the company’s stock are sold short.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Curis in a research note on Friday.

Curis Stock Down 0.8 %

CRIS stock opened at $3.95 on Friday. The business’s 50-day moving average is $5.01 and its two-hundred day moving average is $7.12. Curis has a 1 year low of $3.51 and a 1 year high of $17.49.

Institutional Trading of Curis

Several hedge funds have recently added to or reduced their stakes in the company. Focused Wealth Management Inc grew its holdings in Curis by 63.1% during the 3rd quarter. Focused Wealth Management Inc now owns 54,066 shares of the biotechnology company’s stock worth $291,000 after acquiring an additional 20,908 shares in the last quarter. Point72 Asset Management L.P. grew its stake in shares of Curis by 795.5% during the second quarter. Point72 Asset Management L.P. now owns 108,356 shares of the biotechnology company’s stock worth $748,000 after purchasing an additional 96,256 shares in the last quarter. CM Management LLC grew its stake in shares of Curis by 380.0% during the first quarter. CM Management LLC now owns 120,000 shares of the biotechnology company’s stock worth $1,304,000 after purchasing an additional 95,000 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in Curis by 4.8% in the first quarter. Vanguard Group Inc. now owns 218,573 shares of the biotechnology company’s stock valued at $2,376,000 after buying an additional 10,097 shares during the last quarter. Institutional investors and hedge funds own 29.97% of the company’s stock.

Curis Company Profile

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.